Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Mylan Reports 3Q Loss on Revenue Drop And Legal Costs

By Pharmaceutical Processing | October 29, 2009

PITTSBURGH (AP) — Mylan Inc. said Thursday it posted a loss during the third quarter on a mix of lower revenue and costs for a legal settlement. The company lost $40 million, or 13 cents per share, compared with profit of $182.4 million, or 47 cents per share, a year earlier. Revenue slid 24 percent to $1.26 billion from $1.66 billion, mainly because of a tough comparison. In the prior year’s third quarter, the company received a $455 million boost to revenue from the sale of Bystolic product rights. It had no such additional revenue in the most recent quarter. Mylan said its adjusted earnings per share reached 32 cents, while analysts polled by Thomson Reuters expected profit of 27 cents per share on revenue of $1.23 billion. During the quarter, Mylan recorded a $121 million charge to settle a Medicaid drug rebate issue with the U.S. Department of Justice. Total generic drug revenue rose 3.7 percent, to $1.12 billion from $1.08 billion. North American revenue rose 9.2 percent to $502.5 million. Looking ahead, the company boosted its profit guidance to a range of $1.24 to $1.28 per share. In July, it set guidance at $1.13 to $1.20 per share. Analysts expect full-year profit of $1.17 per share. In premarket trading, Mylan shares rose 53 cents, or 3.4 percent, to $16.30.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE